Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Oct 3;5(10):898-903.
doi: 10.1016/j.jdcr.2019.07.015. eCollection 2019 Oct.

Nonbullous pemphigoid secondary to PD-1 inhibition

Sean Singer  1 , Caroline A Nelson  1   2 , Christian G Lian  3 , Anna K Dewan  4 , Nicole R LeBoeuf  1   2
Affiliations
Case Reports

Nonbullous pemphigoid secondary to PD-1 inhibition

Sean Singer et al. JAAD Case Rep. .
No abstract available

Keywords: BP, bullous pemphigoid; BP180, anti–bullous pemphigoid 180; BP230, anti–bullous pemphigoid 230; DIF, direct immunofluorescence; ELISA, enzyme-linked immunosorbent assay; ICI, immune checkpoint inhibitor; IIF, indirect immunofluorescence; Ig, immunoglobulin; NBP, nonbullous pemphigoid; PD-1; PD-1, programmed cell death 1; bullous pemphigoid; immune checkpoint inhibitor; immune-related adverse event; nonbullous pemphigoid.

PubMed Disclaimer

Figures

Fig 1
Fig 1
A, Clinical presentation of case 1. Erythematous papules coalescing into plaques on the lower portion of the back. B, Histopathology of case 1. Eosinophilic spongiosis with tagging of eosinophils at dermal-epidermal junction.
Fig 2
Fig 2
Other clinical images of nonbullous pemphigoid secondary to programmed cell death 1 inhibitor therapy. A, Pink edematous papules on the trunk in case 2. B, Urticarial plaques with central scale on the lower portion of the back in case 3.
See this image and copyright information in PMC

References

    1. Lamberts A., Meijer J.M., Jonkman M.F. Nonbullous pemphigoid: A systematic review. J Am Acad Dermatol. 2018;78(5):989–995. - PubMed
    1. Cozzani E., Gasparini G., Burlando M., Drago F., Parodi A. Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects. Autoimmun Rev. 2015;14(5):438–445. - PubMed
    1. Damsky W., Kole L., Tomayko M.M. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep. 2016;2(6):442–444. - PMC - PubMed
    1. Siegel J., Totonchy M., Damsky W. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79(6):1081–1088. - PubMed
    1. Lopez A.T., Khanna T., Antonov N., Audrey-Bayan C., Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57(6):664–669. - PubMed

Publication types

LinkOut - more resources